Program
Prednisone
Also written as “prednisone”, “CHOP” and “Lodotra®”.
Its studies are mostly in Prostatic Neoplasms · Lymphoma, Large B-Cell, Diffuse · Arthritis, Rheumatoid · Lymphoma, T-Cell, Peripheral · Asthma, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 40 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Sanofi | 40 open or running | phase 4since Jul 20, 2012 | Mar 3, 2011 | none ahead |
| Bristol-Myers Squibb | 30 open or running | phase 2since Apr 19, 2007 | Apr 19, 2007 | none ahead |
| Takeda | 31 open or running | phase 3since Jul 25, 2007 | Jul 25, 2007 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 4since Jul 8, 2014 | Jul 8, 2014 | none ahead |
| Eli Lilly | 21 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Mundipharma | 20 open or running | phase 4since Feb 14, 2014 | Mar 14, 2013 | none ahead |
| Amgen | 10 open or running | phase 2since May 26, 2008 | May 26, 2008 | none ahead |
| ampel-biosolutions-llc | 10 open or running | phase 4since Mar 21, 2017 | Mar 21, 2017 | none ahead |
| caredx | 11 open or running | no phasesince Oct 21, 2026 | Oct 21, 2026 | Dec 2028NCT07905599 |
| Ionis Pharmaceuticals | 10 open or running | phase 2since Nov 2, 2010 | Nov 2, 2010 | none ahead |
| Oncotherapeutics | 10 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| Sumitomo Pharma | 10 open or running | phase 1since Dec 7, 2020 | Dec 7, 2020 | none ahead |
Also a collaborator on its studies: AbbVie, basilea-pharmaceutica-international-ltd and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Nov 1, 1999.
- Feb 14, 2014Phase 4 study in Arthritis, RheumatoidMundipharma · NCT02072200 · 147 enrolled · Korea, Republic of
- Feb 26, 2014Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02074137 · 10 enrolled · India
- Jul 8, 2014Boehringer Ingelheim's first study: phase 4 study in HIV InfectionsNew to Boehringer IngelheimBoehringer Ingelheim · NCT02184299 · 138 enrolled
- Jul 30, 2014Oncotherapeutics's first study: phase 2 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT02206425 · 45 enrolled · United States
- Oct 16, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02268149 · 20 enrolled
- Apr 21, 2016Phase 1 study in Healthy AdultsPfizer · NCT02767089 · 37 enrolled · United States
- May 4, 2016Phase 2 study in Carcinoma, Renal CellBristol-Myers Squibb · NCT02763761 · United States
- Dec 22, 2016Phase 2 study in Lymphoma, Large B-Cell, DiffuseBristol-Myers Squibb · NCT03003520 · 46 enrolled · United States, Austria, Denmark and more
- Mar 21, 2017ampel-biosolutions-llc's first study: phase 4 study in Lupus Erythematosus, SystemicNew to ampel-biosolutions-llcampel-biosolutions-llc · NCT03098823 · 62 enrolled · United States
- May 11, 2020Eli Lilly's first study: phase 2 study in Gaucher DiseaseNew to Eli LillyEli Lilly · NCT04411654 · 7 enrolled · United States, United Kingdom
- Dec 7, 2020Sumitomo Pharma's first study: phase 1 study in Metastatic Castration-Resistant Prostate CancerNew to Sumitomo PharmaSumitomo Pharma · NCT04666129 · 48 enrolled · United States
- Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
- Nov 1, 2023Phase 1 study in Dermatitis, AtopicEli Lilly · NCT06119529 · 18 enrolled · United States
- Oct 21, 2026caredx's first study: no phase study in Heart Transplant RejectionNew to caredxcaredx · NCT07905599 · 200 planned
Ahead
- Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
- Dec 2028Primary completion: no phase study in Heart Transplant Rejectioncaredx · NCT07905599
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07905599Heart Transplant Rejection | – | Not yet recruiting | caredx | Dec 2028 | 200 |
| NCT06119529Dermatitis, Atopic · United States | 1 | Terminated | Eli Lilly | Apr 8, 2024 | 18 |
| NCT05673785Lymphoma · China | 2 | Active, not recruiting | Takeda | Apr 27, 2025 | 52 |
| NCT04666129Metastatic Castration-Resistant Prostate Cancer · United States | 1 | Completed | Sumitomo Pharma | May 28, 2024 | 48 |
| NCT04411654Gaucher Disease · United States, United Kingdom | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 7 |
| NCT03098823Lupus Erythematosus, Systemic · United States | 4 | Completed | ampel-biosolutions-llc | May 28, 2019 | 62 |
| NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Apr 24, 2022 | 46 |
| NCT02763761Carcinoma, Renal Cell · United States | 2 | Withdrawn | Bristol-Myers Squibb | Mar 31, 2017 | 0 |
| NCT02767089Healthy Adults · United States | 1 | Completed | Pfizer | Mar 2006 | 37 |
| NCT02268149Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2000 | 20 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02184299HIV Infections | 4 | Completed | Boehringer Ingelheim | Jan 2000 | 138 |
| NCT02074137Prostate Cancer Metastatic · India | 4 | Completed | Sanofi | Mar 2016 | 10 |
| NCT02072200Arthritis, Rheumatoid · Korea, Republic of | 4 | Completed | Mundipharma | Apr 2015 | 147 |
| NCT01821040Polymyalgia Rheumatica · United Kingdom | 3 | Terminated | Mundipharma | Apr 2014 | 62 |
| NCT01649635Prostatic Neoplasms · Brazil | 4 | Completed | Sanofi | Jan 2014 | 45 |
| NCT01511536Prostatic Neoplasms · United States, France, United Kingdom | 2 | Completed | Sanofi | Jul 2014 | 38 |
| NCT01393639Arthritis, Rheumatoid · United States, Bulgaria, Colombia and more | 2 | Completed | Pfizer | Jun 3, 2014 | 323 |
| NCT01308580Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Aug 2015 | 1,200 |
| NCT01234025Castrate-Resistant Prostate Cancer · United States, Hungary, Poland and more | 2 | Completed | Ionis Pharmaceuticals | May 2013 | 113 |
| NCT00715208Lymphoma, Follicular · United States, Puerto Rico | 2 | Completed | Takeda | Feb 2011 | 55 |
| NCT00686335Asthma · France | 2 | Completed | Amgen | Mar 2010 | 12 |
| NCT00507416Multiple Myeloma · United States, Puerto Rico | 3 | Completed | Takeda | Mar 2013 | 502 |
| NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more | 2 | Completed | Bristol-Myers Squibb | May 1, 2009 | 88 |
| NCT00004071Prostatic Neoplasms · United States | 3 | Completed | Pfizer | Sep 2007 | |
| NCT00003343Prostatic Neoplasms · United States | 3 | Completed | Pfizer | Jan 2001 | 525 |
How it is read
Names in the registry
- “Prednisone”, 39 entries
- “prednisone”, 7 entries
- “CHOP”, 2 entries
- “Lodotra®”, 2 entries
- “Abiraterone/prednisone”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 18 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Arthritis, Rheumatoid, 4 studies
- Lymphoma, T-Cell, Peripheral, 3 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.